Bupropion for smokers hospitalized with acute cardiovascular disease.

Bupropion for smokers hospitalized with acute cardiovascular disease. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Bupropion for smokers hospitalized with acute cardiovascular disease. Abstract Text:

Nancy A Rigotti,Anne N Thorndike,Susan Regan,Kathleen McKool,Richard C Pasternak,Yuchiao Chang,Susan Swartz,Nancy Torres-Finnerty,Karen M Emmons,Daniel E Singer,

PURPOSE: Smoking cessation after myocardial infarction reduces cardiovascular mortality, but many smokers cannot quit despite state-of-the-art counseling intervention. Bupropion is effective for smoking cessation, but its safety and efficacy in hospitalized smokers with acute cardiovascular disease is unknown. METHODS: A five-hospital randomized double-blind placebo-controlled trial assessed the safety and efficacy of 12 weeks of sustained-release bupropion (300 mg) or placebo in 248 smokers admitted for acute cardiovascular disease, primarily myocardial infarction and unstable angina. All subjects had smoking counseling in the hospital and for 12 weeks after discharge. Cotinine-validated 7-day tobacco abstinence, cardiovascular mortality, and new cardiovascular events were assessed at 3 months (end-of-treatment) and 1 year. RESULTS: Validated tobacco abstinence rates in bupropion and placebo groups were 37.1% vs 26.8% (OR 1.61, 95% CI, 0.94-2.76; P=.08) at 3 months and 25.0% vs 21.3% (OR, 1.23, 95% CI, 0.68-2.23, P=.49) at 1 year. The adjusted odds ratio, after controlling for cigarettes per day, depression symptoms, prior bupropion use, hypertension, and length of stay, was 1.91 (95% CI, 1.06-3.40, P=.03) at 3 months and 1.51 (95% CI, 0.81-2.83) at 1 year. Bupropion and placebo groups did not differ in cardiovascular mortality at 1 year (0% vs 2%), in blood pressure at follow-up, or in cardiovascular events at end-of-treatment (16% vs 14%, incidence rate ratio [IRR]1.22 (95% CI: 0.64-2.33) or 1 year (26% vs 18%, IRR 1.56, 95% CI 0.91-2.69). CONCLUSIONS: Bupropion improved short-term but not long-term smoking cessation rates over intensive counseling and appeared to be safe in hospitalized smokers with acute cardiovascular disease.

Bupropion for smokers hospitalized with acute cardiovascular disease. Publishing Authors By Initials

NA Rigotti,AN Thorndike,S Regan,K McKool,RC Pasternak,Y Chang,S Swartz,N Torres-Finnerty,KM Emmons,DE Singer,

For similar behavior and behavior mechanisms: behavior: habits: smoking research abstracts see: behavior and behavior mechanisms: behavior: habits: smoking research

PUBMED ID PMID:

MEDLINE DATE:

Bupropion for smokers hospitalized with acute cardiovascular disease. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: The American journal of medicine

VOLUME: 119

Page Numbers: 1080-7

Journal Abbreviation: Am. J. Med.

ISSN: 1555-7162

DAY: 3

MONTH: Dec

YEAR: 2006

Bupropion for smokers hospitalized with acute cardiovascular disease. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 267200

Bupropion for smokers hospitalized with acute cardiovascular disease. Keywords Mesh Terms:

KEYWORDS: Smoking

MESH TERMS: drug therapy

Chemical & Substance for Abstract: Bupropion for smokers hospitalized with acute cardiovascular disease. Information

Substance Name: Bupropion

Registry Number: 34841-39-9

Grant and Affiliation Information for Bupropion for smokers hospitalized with acute cardiovascular disease.

AFFILIATION: Tobacco Research and Treatment Center, General Medicine Division, and Cardiology Division, Massachusetts General Hospital and Harvard Medical School, Boston, Mass 02114, USA. nrigotti@partners.org

Country: United States

AGENCY: United States NHLBI

GRANT: R01 HL 61779

ACRONYM: HL

MEDLINETA: Am J Med

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Bupropion for smokers hospitalized with acute cardiovascular disease Related Publications

• A longitudinal case study of a child with mosaic trisomy 22: language, cognitive, behavioral, physical, and dental outcomes.
• A progressive, fatal dystonia-Parkinsonism syndrome in a patient with primary immunodeficiency receiving chronic IVIG therapy.
• A recipe for randomness.
• Aggressive drug marketing tactics trigger backlash.
• Bupropion for smokers hospitalized with acute cardiovascular disease.
• Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma.
• Combinations of biomarkers predictive of later life mortality.
• Constitutive turnover of cyclin E by Cul3 maintains quiescence.
• Detection and Classification of Movements in Bed using Load Cells.
• Education correction using years in school or reading grade-level equivalent? Comparing the accuracy of two methods in diagnosing HIV-associated neurocognitive impairment.
• Frontal dopaminergic abnormality in Tourette syndrome: a postmortem analysis.
• In vivo dynamics of RNA polymerase II transcription.
• Laryngeal dystonia as a presenting symptom of young-onset Parkinson's disease.
• Mast cell-mediated changes in smooth muscle contractility during mouse giardiasis.
• Metastasis to the submandibular gland in head and neck carcinomas.
• Norepinephrine transporter polymorphisms in Tourette syndrome with and without attention deficit hyperactivity disorder: no evidence for significant association.
• Postdischarge treatment costs following closure of a state geropsychiatric ward: comparison of 2 levels of community care.
• Prenatal cocaine and tobacco effects on children's language trajectories.
• Role of the brain-gut axis in alcohol-related gastrointestinal diseases--what can we learn from new animal models?
• Selective effects of cyclosporin A on colony-forming lymphoid and myeloid cells in man.
• Sleep and sleep disturbance: from genes to dreams.
• The Cullin3 ubiquitin ligase functions as a Nedd8-bound heterodimer.
• The aging experience of well elderly women: initial results.
• The headache doctor: the dog ate my pills and other tales of woe.
• The validity of the 2004 U.S. News & World Report's rankings of schools of social work: a response.
• Tic disorders: neural circuits, neurochemistry, and neuroimmunology.
• Tumour necrosis factor alpha contributes to protection against Giardia lamblia infection in mice.
• Within-trial contrast: pigeons prefer conditioned reinforcers that follow a relatively more rather than a less aversive event.
• [Ectopic prostatic tissue in the uterine cervix]
• [Meningothelial meningioma in a mature cystic teratoma of the ovary]